Author: Lauren Giorgio

  Adelaide, Australia - 7th May 2024  GPN Vaccines Ltd is pleased to announce the successful award of $936,000 in Round 3 of Brandon BioCatalyst’s CUREator Program. This funding marks an important milestone in the Company's journey toward advancing its novel pneumococcal vaccine, Gamma-PN. Funding from the CUREator...

Adelaide, Australia GPN Vaccines is pleased to announce that Dr Erin Brazel has been awarded a Junior Fellowship by the Passe & Williams Memorial Foundation. The prestigious fellowship secured by Dr Erin Brazel will support research on bacterial vaccines in a collaboration between GPN Vaccines and the...

Adelaide, Australia GPN Vaccines Ltd, a clinical-stage biotechnology company developing a Streptococcus pneumoniae vaccine to prevent life-threatening pneumonia, bacteraemia and meningitis, is pleased to announce positive safety and immunogenicity data from its Phase 1 trial of Gamma-PN, a non-adjuvanted whole cell-pneumococcal vaccine being investigated in adults aged...

GPN Vaccines was initially established with the goal of creating a vaccine capable of protecting children and adults against all serotypes of Streptococcus pneumoniae (the pneumococcus), a deadly pathogen responsible for killing up to two million people worldwide each year. Such a vaccine represents the...

Adelaide, Australia, 21st September 2022 - GPN Vaccines is pleased to announce publication of a landmark scientific paper in the prestigious journal mBio showing its novel pneumococcal vaccine, Gamma-PN, elicits a broad-spectrum, serotype-independent opsonophagocytic antibody response. This research, conducted in collaboration with the University of Adelaide,...

Protecting children and adults from the world’s foremost bacterial pathogen